Evaluation of efficacy and tolerance sumatriptan at a dose of 50 mg in treatment of migraine attack
Sumatriptan has been used successfully in the acute treatment of migraine since 1991. Most patients (70-80%) experience pain relief 2-4 hours after receiving 100 mg sumatriptan orally. During last few years efficacy of lower doses has been studied. Many authors proved that 50 mg of sumatriptan may be as effective as 100 mg. Our study confirmed that 50 mg oral dose of sumatriptan is sufficient in many patients. Headache relief was achieved in 58% of treated patients after single dose. The second dose of sumatriptan was effective in next 14% of patients. Totally headache relief after two doses of sumatriptan was achieved in 72% of patients. The sumatriptan 50 mg was well tolerated; only 10% of patients reported adverse events, which were minor and transient.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1998 |
|---|---|
| Erschienen: |
1998 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego - 4(1998), 21 vom: 08. März, Seite 158-61 |
| Sprache: |
Polnisch |
|---|
| Weiterer Titel: |
Ocena skuteczności i tolerancji sumatryptanu w dawce 50 mg w leczeniu napadu migreny |
|---|
| Beteiligte Personen: |
Prusiński, A [VerfasserIn] |
|---|
| Themen: |
8R78F6L9VO |
|---|
| Anmerkungen: |
Date Completed 14.07.1998 Date Revised 21.11.2013 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM095801006 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM095801006 | ||
| 003 | DE-627 | ||
| 005 | 20231222102524.0 | ||
| 007 | tu | ||
| 008 | 231222s1998 xx ||||| 00| ||pol c | ||
| 028 | 5 | 2 | |a pubmed24n0320.xml |
| 035 | |a (DE-627)NLM095801006 | ||
| 035 | |a (NLM)9640070 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a pol | ||
| 100 | 1 | |a Prusiński, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of efficacy and tolerance sumatriptan at a dose of 50 mg in treatment of migraine attack |
| 246 | 3 | 3 | |a Ocena skuteczności i tolerancji sumatryptanu w dawce 50 mg w leczeniu napadu migreny |
| 264 | 1 | |c 1998 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 14.07.1998 | ||
| 500 | |a Date Revised 21.11.2013 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Sumatriptan has been used successfully in the acute treatment of migraine since 1991. Most patients (70-80%) experience pain relief 2-4 hours after receiving 100 mg sumatriptan orally. During last few years efficacy of lower doses has been studied. Many authors proved that 50 mg of sumatriptan may be as effective as 100 mg. Our study confirmed that 50 mg oral dose of sumatriptan is sufficient in many patients. Headache relief was achieved in 58% of treated patients after single dose. The second dose of sumatriptan was effective in next 14% of patients. Totally headache relief after two doses of sumatriptan was achieved in 72% of patients. The sumatriptan 50 mg was well tolerated; only 10% of patients reported adverse events, which were minor and transient | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Vasoconstrictor Agents |2 NLM | |
| 650 | 7 | |a Sumatriptan |2 NLM | |
| 650 | 7 | |a 8R78F6L9VO |2 NLM | |
| 700 | 1 | |a Król, F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego |d 1997 |g 4(1998), 21 vom: 08. März, Seite 158-61 |w (DE-627)NLM090955315 |x 1426-9686 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:1998 |g number:21 |g day:08 |g month:03 |g pages:158-61 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 1998 |e 21 |b 08 |c 03 |h 158-61 | ||